Zolmitriptan

SKU: orb1309803

Description

Zolmitriptan is a selective serotonin 5-HT1B/1D receptor agonist from the triptan class, used in migraine research. Its mechanism involves cranial vasoconstriction and inhibition of peripheral and central trigeminal nociceptive pathways, which can be studied in both in vitro receptor binding assays and in vivo migraine models.

Research Area

Metabolism Research, Neuroscience, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 139264-17-8
• MW: 287.36
• Purity: 98.80%
• Formula: C₁₆H₂₁N₃O₂
• SMILES: C(CN(C)C)C=1C=2C(NC1)=CC=C(C[C@@H]3NC(=O)OC3)C2
• Target: Endogenous Metabolite,5-HT Receptor
• Solubility: DMSO:55 mg/mL (191.4 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.96 mM);Ethanol:28.7 mg/mL (99.87 mM)

Bioactivity

• Target IC50:
  5-HT1B receptor:5.01 nM (Ki)|5-HT1D receptor:0.63 nM (Ki)|5-HT1F receptor:63.09 nM (Ki)
• In Vivo:
  Zolmitriptan (3-30 mg/kg, i.v.) administrated ten minutes before unilateral electrical stimulation of the trigeminal ganglion causes a dose-dependent inhibition of [125I]-albumin extravasation within the ipsilateral dura mater in anaesthetized guinea-pigs. Zolmitriptan (10-1000 mg/kg, i.v.) selectively reduces arteriovenous-anastomotic (AVA) conductance producing a maximum decrease of 92.5%. Zolmitriptan also produces a modest reduction in extra-cerebral conductance (23.9% maximum reduction at 30 mg/kg, i.v.), but is without effect on cerebral conductance. Zolmitriptan (1-30 mg/kg, i.v.) produces dose-dependent decreases in ear microvascular conductance (15% to 60%) which mirror decreases in carotid arterial conductance in anaesthetised cats. Zolmitriptan exerts behaviorally specific anti-aggressive effects in mice. Zolmitriptan also decreases alcohol-heightened aggression with equal efficacy in mice.
• In Vitro:
  Zolmitriptan produces concentration-dependent contractions of primate basilar artery and human epicardial coronary artery rings. Zolmitriptan displays high affinity at human recombinant 5-HT1D (formerly 5-HT1D alpha) and 5-HT1B (formerly 5-HT1D beta) receptors in transfected CHO-K1 cell membranes. Zolmitriptan increases I(K) in a concentration-dependent manner (maximum increase 16.3%) with a pD(2) value of 7.03 in C6 glioma cells expressing recombinant human 5-HT(1B) receptor. Zolmitriptan-induced increases in I(K) are prevented by the calcium chelator, EGTA (5 mM) when included in the patch pipette in C6 cells expressing cloned human 5-HT(1B) receptors.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Endogenous Metabolite, BW-311C90, 311C90, 5-HT, 5-hydroxytryptamine Receptor, 5HTReceptor, 5HT Receptor, 5-HT,migraine, 5-HT Receptor, inhibit, muscle, neurogenic, Inhibitor, input, motoneurons, extravasation, Zolmitriptan, triptans, synaptic, spasms, spasticity, serotonin, Serotonin Receptor

Compound Identifiers

PubChem CID

60857